» Articles » PMID: 29377313

SOST/Sclerostin Improves Posttraumatic Osteoarthritis and Inhibits MMP2/3 Expression After Injury

Overview
Date 2018 Jan 30
PMID 29377313
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Patients with anterior cruciate ligament (ACL) rupture are two times as likely to develop posttraumatic osteoarthritis (PTOA). Annually, there are ∼900,000 knee injuries in the United States, which account for ∼12% of all osteoarthritis (OA) cases. PTOA leads to reduced physical activity, deconditioning of the musculoskeletal system, and in severe cases requires joint replacement to restore function. Therefore, treatments that would prevent cartilage degradation post-injury would provide attractive alternatives to surgery. Sclerostin (Sost), a Wnt antagonist and a potent negative regulator of bone formation, has recently been implicated in regulating chondrocyte function in OA. To determine whether elevated levels of Sost play a protective role in PTOA, we examined the progression of OA using a noninvasive tibial compression overload model in SOST transgenic (SOST ) and knockout (Sost ) mice. Here we report that SOST mice develop moderate OA and display significantly less advanced PTOA phenotype at 16 weeks post-injury compared with wild-type (WT) controls and Sost . In addition, SOST built ∼50% and ∼65% less osteophyte volume than WT and Sost , respectively. Quantification of metalloproteinase (MMP) activity showed that SOST had ∼2-fold less MMP activation than WT or Sost , and this was supported by a significant reduction in MMP2/3 protein levels, suggesting that elevated levels of SOST inhibit the activity of proteolytic enzymes known to degrade articular cartilage matrix. Furthermore, intra-articular administration of recombinant Sost protein, immediately post-injury, also significantly decreased MMP activity levels relative to PBS-treated controls, and Sost activation in response to injury was TNFα and NF-κB dependent. These results provide in vivo evidence that sclerostin functions as a protective molecule immediately after joint injury to prevent cartilage degradation. © 2018 The Authors. Journal of Bone and Mineral Research Published by Wiley Periodicals Inc.

Citing Articles

Articular cartilage loss is an unmitigated risk of human spaceflight.

Hardy J NPJ Microgravity. 2024; 10(1):104.

PMID: 39543227 PMC: 11564753. DOI: 10.1038/s41526-024-00445-w.


Animal Models of Osteoarthritis: Updated Models and Outcome Measures 2016-2023.

Chapman J, Ghosh D, Attari S, Ude C, Laurencin C Regen Eng Transl Med. 2024; 10(2):127-146.

PMID: 38983776 PMC: 11233113. DOI: 10.1007/s40883-023-00309-x.


Identification of key genes and immune infiltration in osteoarthritis through analysis of zinc metabolism-related genes.

You X, Ye Y, Lin S, Zhang Z, Guo H, Ye H BMC Musculoskelet Disord. 2024; 25(1):227.

PMID: 38509535 PMC: 10956297. DOI: 10.1186/s12891-024-07347-8.


Knee osteoarthritis: A review of animal models and intervention of traditional Chinese medicine.

Song X, Liu Y, Chen S, Zhang L, Zhang H, Shen X Animal Model Exp Med. 2024; 7(2):114-126.

PMID: 38409942 PMC: 11079151. DOI: 10.1002/ame2.12389.


Osteocyte-derived sclerostin impairs cognitive function during ageing and Alzheimer's disease progression.

Shi T, Shen S, Shi Y, Wang Q, Zhang G, Lin J Nat Metab. 2024; 6(3):531-549.

PMID: 38409606 DOI: 10.1038/s42255-024-00989-x.


References
1.
Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier J, Fahmi H . Role of proinflammatory cytokines in the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 2010; 7(1):33-42. DOI: 10.1038/nrrheum.2010.196. View

2.
Velasco J, Zarrabeitia M, Prieto J, Perez-Castrillon J, Perez-Aguilar M, Perez-Nunez M . Wnt pathway genes in osteoporosis and osteoarthritis: differential expression and genetic association study. Osteoporos Int. 2009; 21(1):109-18. DOI: 10.1007/s00198-009-0931-0. View

3.
Chan B, Fuller E, Russell A, Smith S, Smith M, Jackson M . Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage. 2011; 19(7):874-85. DOI: 10.1016/j.joca.2011.04.014. View

4.
Collette N, Genetos D, Economides A, Xie L, Shahnazari M, Yao W . Targeted deletion of Sost distal enhancer increases bone formation and bone mass. Proc Natl Acad Sci U S A. 2012; 109(35):14092-7. PMC: 3435175. DOI: 10.1073/pnas.1207188109. View

5.
Li X, Ominsky M, Niu Q, Sun N, Daugherty B, DAgostin D . Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008; 23(6):860-9. DOI: 10.1359/jbmr.080216. View